ArticleInternational journal of nanomedicine2026
PD-L1 Aptamer-Functionalized Mesoporous Silica Nanoparticles for Targeted Doxorubicin Delivery in Triple-Negative Breast Cancer.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological modulation of cGAS-STING-NLRP3 signaling by nano-immunomodulators in Alzheimer and Parkinson disease.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) remains highly aggressive and lacks effective molecularly targeted therapies. Programmed death-ligand 1 (PD-L1) represents a potential cell-surface target for selective drug delivery. Objective: To develop and evaluate a PD-L1 aptamer-functionalized mesoporous silica nanoparticle system loaded with doxorubicin (Apt-PD-L1-MSN/DOX) for targeted DOX delivery in TNBC. Methods: Apt-PD-L1-MSN/DOX was synthesized and characterized by TEM, DLS, zeta-potential measurement, FT-IR, and UV-Vis analysis. DOX release was evaluated at pH 7.4, 6.5, and 5.0. Cellular targeting, cytotoxicity, and aptamer-blocking effects were assessed in MDA-MB-231 and MCF-10A cells. In vivo fluorescence distribution, antitumor efficacy, and short-term safety were evaluated in MDA-MB-231 xenograft-bearing mice. Results: Aptamer functionalization increased the hydrodynamic diameter from approximately 95 to 106 nm, with an estimated surface-associated aptamer loading of ~6.65 nmol/mg. DOX release was pH dependent, remaining below 40% at pH 7.4 but exceeding 80% at pH 5.0 after 96 h. Apt-PD-L1-MSN/DOX showed enhanced cellular targeting and the lowest IC Conclusion: Apt-PD-L1-MSN/DOX shows promise as a PD-L1 aptamer-guided platform for targeted DOX delivery in the evaluated TNBC model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.